Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”)
is today displaying an important ePoster at IDWeek 2021. IDWeek is
the joint annual meeting of the Infectious Diseases Society of
America (IDSA), Society for Healthcare Epidemiology of America
(SHEA), the HIV Medical Association (HIVMA), the Pediatric
Infectious Diseases Society (PIDS), and the Society of Infectious
Diseases Pharmacists (SIDP). Summit’s ePoster provides enhanced
details regarding the newly discovered novel mechanism of action of
ridinilazole. The ePoster will be available throughout IDWeek 2021,
which takes place between September 29 and October 3, 2021.
Ridinilazole is Summit Therapeutics’
investigational first-in-class drug that recently completed
enrollment of a Phase III clinical trial, Ri-CoDIFy. The primary
endpoint of this trial seeks to demonstrate the superiority of
ridinilazole in sustained clinical response as compared to
vancomycin. Ridinilazole is not currently approved for use by any
regulatory authority.
Summit’s poster presentation provides
demonstrable scientific evidence of ridinilazole’s novel mechanism
of action which involves binding to the minor groove of
Clostridioides difficile bacteria’s DNA (the minor groove is a
location on the helix of the bacteria’s DNA to which a drug can
attach or bind). This is believed to be the primary mechanism
through which ridinilazole elicits its bactericidal action against
C. difficile bacteria. Ridinilazole has a novel mechanism of action
and is the first of a new class of antibiotics: this is
consistent with the World Health Organization’s (WHO)
recommendation for developing antibiotics with novel mechanisms of
action or that are new classes of drugs, which it considers a key
point in overcoming existing bacterial resistance.1
Our updated research, through collaboration with
the University of Houston, provides new images from high-resolution
confocal microscopy. This technique has allowed intracellular
visualization of ridinilazole binding to DNA within C. difficile
and confirms this novel mechanism of action. Ridinilazole, if
approved, has the potential to be the first antibiotic with a novel
mechanism of action approved in over ten years.
The poster is available within the “Scientific
Literature & Publications” section of our website:
https://www.summittxinc.com/publications/.
About Summit Therapeutics
The overriding objective of Summit Therapeutics
is to create value for patients, hospital caregivers, and
community-based healthcare providers, as well as healthcare payers
around the world. We seek to create value by developing drugs with
high therapeutic efficacy - curing the cause of the patient's
condition with minimal or zero disease recurrence or antimicrobial
resistance, for the longest extent possible - and minimizing the
trauma caused to the patient and healthcare ecosystem by minimizing
serious side effects, disease recurrence, and inaccessibility to
our treatments as a result of financial or other barriers. Summit
Therapeutics, empowered by its Discuva Platform, the Company’s
innovative antibiotic discovery engine, and supported by BARDA and
CARB-X funding, intends to be the leader in patient-friendly and
paradigm-shifting treatments for infectious diseases and other
significant unmet medical needs while being an ally to physicians.
Our new mechanism pipeline product candidates are designed with the
goal to become the patient-friendly, new-era standard of care, by
working in harmony with the human microbiome to treat prospective
patients suffering from infectious diseases, initially focusing on
Clostridioides difficile infection (CDI). Currently, Summit’s lead
product candidate, ridinilazole, is a novel, first-in-class drug
engaged in a global Phase III trial program versus vancomycin, for
use as first-line therapy for the treatment of initial and
recurrent Clostridioides difficile infection, and to show
superiority in sustained clinical response. Commercialization of
ridinilazole is subject to regulatory approvals. SMT-738, the
second candidate within Summit’s portfolio, is currently in the
IND-enabling phase for the treatment of multidrug resistant
infections, specifically those caused by carbapenem-resistant
Enterobacteriaceae (CRE).
For more information, please visit https://www.summittxinc.com
and follow us on Twitter @summitplc. For more information on the
Company’s Discuva Platform, please visit
https://www.summittxinc.com/our-science/discuva-platform.
About C. difficile Infection
Clostridioides difficile, or C. difficile,
infection (CDI) is a bacterial infection of the colon that produces
toxins causing inflammation of the colon, severe watery diarrhea,
painful abdominal cramping, nausea, fever, and dehydration. CDI can
also result in more serious disease complications, including bowel
perforation, sepsis, and death. CDI is a contagious infectious
disease that represents a serious healthcare issue in hospitals,
long-term care facilities, and the wider community. Summit
estimates that there are approximately 500,000 cases of CDI each
year across the United States with acute care costs exceeding $5.4
billion in the US based on a meta-analysis published in the Journal
of Global Health, June 2019.
Contact Summit Investor Relations
Dave GancarzHead of Investor Relations &
Corporate Strategydavid.gancarz@summitplc.com
General Inquiries:investors@summitplc.com
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the timing
of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals, the impact of the COVID-19 pandemic on the Company’s
operations and clinical trials and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "would," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, global public health crises,
including the coronavirus COVID-19 outbreak, that may affect timing
and status of our clinical trials and operations, whether
preliminary results from a clinical trial will be predictive of the
final results of that trial or whether results of early clinical
trials or preclinical studies will be indicative of the results of
later clinical trials, expectations for regulatory approvals, laws
and regulations affecting government contracts and funding awards,
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the "Risk Factors"
section of filings that the Company makes with the Securities and
Exchange Commission. Any change to our ongoing trials could cause
delays, affect our future expenses, and add uncertainty to our
commercialization efforts, as well as to affect the likelihood of
the successful completion of clinical development of ridinilazole.
Accordingly, readers should not place undue reliance on
forward-looking statements or information. In addition, any
forward-looking statements included in this press release represent
the Company’s views only as of the date of this release and should
not be relied upon as representing the Company’s views as of any
subsequent date. The Company specifically disclaims any obligation
to update any forward-looking statements included in this press
release.
1
https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-gcp-irc/five-key-points-to-consider-for-the-development-and-optimal-use-of-new-antibiotics.pdf?sfvrsn=c4a77671_5
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024